SMMT

Summit Therapeutics Inc. is a biopharmaceutical company focused on developing innovative antibiotics and precision medicines for serious infectious diseases and oncology. The company is advancing ivonescimab, a bispecific antibody targeting PD-1 and VEGF for cancer treatment. Summit is conducting global clinical trials to address antibiotic-resistant infections and difficult-to-treat cancers.